| Diabetes mellitus has become a harmful disease with the highest incidence and the high-est mortality in the world, which always requires lifelong treatment. At the same time, much more people are suffering impaired glucose tolerance (IGT) which would turn into diabetes if no health care were taken. The current clinical diabetes and IGT drugs are short of efficacy or rich in side effect. Thus, demand for a novel pharmaceutical with high efficacy and little side effect is necessary and exigent.First, synergetic effect of Oroxylum indicum seed extract (OISE) and acarbose (Acar) on reducing postprandial blood glucose of normal and diabetic rats were assessed. Single use of10mg/kg,100mg/kg OISE,4mg/kg Acar displayed a weak reduction or no significant reduction. However, for normol mice,4mg/kg Acar with different dosage of OISE (10-200mg/kg OISE as the best dosage) could inhibit the rise of both postprandial blood glucose to fasting blood-glucose level and area under curve of glucose, show no significance with20mg/kg Acar group. For diabetic mice,4mg/kg Acar with200mg/kg OISE compound pharmaceutical could significantly inhibit the rise of postprandial blood glucose, even more effective than20mg/kg Acar group.Then, a novel method of modeling mice with impaired glucose tolerance (IGT), with the advantage of high modeling rate and short time period, to give alloxan through Intravenous (IV) route companied with feeding diet containing margarine and sucrose, is established to assess the effect of compound pharmaceutical on IGT. After a8-week drug intervention, glucose tolerance experiment was taken, the result shows the compound pharmaceutical of10、20mg/kg/d OISE and4mg/kg/d could significantly improve glucose tolerance of rats, better then10mg/kg/d,200mg/kg/d OISE;4mg/kg/d,20mg/kg/d acarbose group. Moreover, the effect of compound pharmaceutical varies with the dosage of OISE, but not significantly.Last, in this paper we also studied the effects on blood lipid level and antioxidant capacity by long-term intervention of compound pharmaceutical in IGT mice group. The results suggested that it not only can enhance the high-density lipoprotein concentration and the level of glutathione, reduce the total cholesterol and the low density lipoprotein concentration, but also especially improve hypertriglyceridemia and raise total antioxidation ability. The experimental results showed that the compound pharmaceutical can decrease triglyceride in IGT group by38.3%to43.4%and increase T-AOC by135.9%to192.3%,it also could increase the GSH and T-SOD level while decrease the MDA level in kidney.All these results remind us that the mechanism of the compound drugs to improve IGT can be the eliminatinon of oxidative stess and non-enzymatic glycosylation resulting from high blood glucose by reducing postprandial hyperglycemia. In addition, it can decrease triglycerides to remove peroxidation injury from excessive free fatty acid and increase the glucose absorption of the systemic tissues to enhance the insulin sensitivity insulin on glucose.Compared with model group, compound pharmaceutical could significantly reduce the HbAlc level (47.5%and55.7%, at10mg/kg or200mg/kg OISE, with4mg/kg Acar) which inhibit the pathological changes in micrangium; reduce the risk of atherosclerosis (46.2%and55.7%, respectively) which inhibit the pathological changes in aorta. This reveal that compo-und pharmaceutical could effectively improve the complication produced in the process from IGT to diabetes. Moreover, the effect is better then Acar group.This study not only provide new treatments and prevention plan for diabetes patients and diabetes high-risk groups, will also be lays a foundation for the modernization of traditional Chinese medicine and further development for the new treatment and prevention of diabetes with Integrated traditional and western medicine. |
PDF Full Text Request